[Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial].

PubMed 2026

View at publisher
Authors: A M Zhao, Y Wang, W W Yang, Z Q Liang, Fujin Shen, C Z Li, Z T Wei, Xiujie Sheng, W Yuan, Q Li, F Ming, Y H Zheng
+36 more X Y Lu, H Ye, J J Li, B Lye, H J Ruan, Y Z Zhang, Y X Li, W R Li, H K Yang, Y L Zheng, X J Dong, Hui Lu, Shunyu Hou, P Yan, Y Q Ge, J L Kang, L N Wang, H Y Zhang, Y Hu, R F Zhao, Y L Wang, S Y Zhang, L P Han, Lin Sang, M H Cui, J J Zhai, D Lu, Y Zheng, Y Z Guo, M L Chen, L P Sun, J Lu, S J Guo, X H Zhang, Wen Feng, L H Yang
DOI: 10.3760/cma.j.cn112141-20250421-00161
Cited by: 0

Abstract

Triptorelin acetate microspheres for injection is an effective treatment for endometriosis. It could maintain low estrogen levels, consistently alleviate endometriosis-associated pain, achieve a high rate of amenorrhea during treatment, and reduce the size of ovarian endometrioma to some extent, demonstrating a favorable safety profile.

Fields of Study & Subjects

Endometriosis Research and Treatment Ectopic Pregnancy Diagnosis and Management Endometrial and Cervical Cancer Treatments

Publication details

Journal / source
PubMed
Volume
61
Issue
1
Pages
30–38
Publication date
25 January 2026
Language
ZH